Obagi Cosmeceuticals LLC

Valeant Pharmaceuticals International Inc. has made important debt-reduction progress, meeting its goal ahead of schedule, but the company's near-term growth story remains lackluster. The company tol

China’s healthcare industry has seen an increased level of financing activity in November, with a total of 24 deals in mostly early stage fundraisings for precision medicine and cell therapy. Among th

Just over two years after buying Sprout Pharmaceuticals Inc. and its controversial female sexual dysfunction drug Addyi (flibanserin) for $1bn, Valeant Pharmaceuticals International Inc. has

This year's tally of biopharmaceutical initial public offerings in the US was tied with 2016's total of 30 IPOs when Rhythm Pharmaceuticals Inc. went public on Oct. 5, but 2017 outpaced last year